Stoke Therapeutics (STOK) Non-Current Assets (2018 - 2026)

Stoke Therapeutics' Non-Current Assets history runs 9 years deep, the most recent figure standing at $76.6 million for Q1 2026.

• On a quarterly basis, Non-Current Assets rose 145.88% year-over-year to $76.6 million in Q1 2026; TTM through Mar 2026 was $391.7 million, a 225.27% increase from a year earlier, with the FY2025 full-year figure at $112.7 million, up 190.56% from the prior year.
• Non-Current Assets retreated to $76.6 million in Q1 2026 per STOK's latest filing, from $112.7 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $114.5 million in Q2 2025 and bottomed at $9.9 million in Q3 2023.
• The 5-year median for Non-Current Assets is $13.0 million (2023), against an average of $36.3 million.
• Across the five-year window, Non-Current Assets decreased 24.22% in 2023 and surged 964.18% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $12.0 million in 2022, then grew by 8.39% to $13.0 million in 2023, then surged by 198.38% to $38.8 million in 2024, then soared by 190.56% to $112.7 million in 2025, then slumped by 32.06% to $76.6 million in 2026.
• Per Business Quant, the three latest STOK Non-Current Assets figures stand at $76.6 million (Q1 2026), $112.7 million (Q4 2025), and $87.8 million (Q3 2025).